Pain & Inflammation
Cannabinoids as analgesics — what the evidence actually supports
Chronic pain is the most common reason patients seek medical cannabis in jurisdictions where it is legally available. The evidence base is substantial but heterogeneous — strongest for neuropathic pain and cancer-related pain, more limited for musculoskeletal and inflammatory conditions.
What the Research Shows
Cannabinoids modulate pain through multiple mechanisms: CB1 receptor activation in the dorsal horn of the spinal cord reduces nociceptive transmission; CB2 receptor activation in peripheral tissues reduces neuroinflammation; and TRPV1 desensitization by CBD reduces central sensitization. The clinical evidence is strongest for neuropathic pain — a 2018 Cochrane review of 16 RCTs found moderate-quality evidence for cannabinoids reducing neuropathic pain by at least 30%. For cancer pain, balanced THC:CBD formulations (nabiximols/Sativex) have the most robust RCT evidence. Inflammatory pain (arthritis, IBD) shows promising preclinical data but limited clinical trial evidence. The analgesic effect size for cannabinoids is generally modest — comparable to gabapentinoids — and must be weighed against adverse effects including dizziness, cognitive impairment, and dependency risk.
Key Findings
Cannabinoids reduce neuropathic pain by ~30%
Well-StudiedCochrane review of 16 RCTs found moderate-quality evidence for clinically meaningful neuropathic pain reduction.
THC:CBD ratio matters for cancer pain
Well-StudiedBalanced 1:1 THC:CBD formulations outperform THC-only in cancer pain RCTs, with fewer adverse effects.
CB2 agonism reduces neuroinflammation
Emerging ResearchPreclinical models show CB2 activation reduces microglial activation and pro-inflammatory cytokines by 50–67%.
Opioid-sparing effects observed in observational studies
Emerging ResearchMultiple cohort studies report reduced opioid use in patients using medical cannabis, but RCT evidence is limited.
Featured Studies
View all in libraryCommon Questions
What We Still Don't Know
These are open research questions — areas where the evidence is insufficient or actively contested.
- 1What is the optimal THC:CBD ratio for different pain types?
- 2Does tolerance to cannabinoid analgesia develop, and how quickly?
- 3Can cannabinoids reduce opioid requirements in RCT conditions?
- 4What is the long-term safety profile of cannabinoids for chronic pain?
- 5Which patient subgroups (by genetics, pain type, prior treatment) respond best?